Additionally, prostatic specific antigen (PSA) levels were found to fall in half of the prostate cancer patients, and reduction in other biochemical tumour markers such as CEA and CA125 were also recorded, suggesting antitumour activity. This evidence concerns the gene KLK3 and neoplasm.